Holen Sie sich die Stockscreener-App
2.78
2.21%
0.06
Schlusskurs vom Vortag:
$2.72
Offen:
$2.72
24-Stunden-Volumen:
132.92K
Relative Volume:
0.97
Marktkapitalisierung:
$138.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-41.07M
KGV:
-4.2121
EPS:
-0.66
Netto-Cashflow:
$-32.97M
1W Leistung:
+0.36%
1M Leistung:
+6.11%
6M Leistung:
-10.61%
1J Leistung:
+36.95%
1-Tages-Spanne:
$2.68
$2.82
1-Wochen-Bereich:
$2.646
$2.8992
52-Wochen-Spanne:
$1.555
$4.2684
Galectin Therapeutics Inc Stock (GALT) Company Profile
Firmenname
Galectin Therapeutics Inc
Sektor
Branche
Telefon
678-620-3186
Adresse
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Vergleichen Sie GALT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| GALT | 2.78 | 138.59M | 0 | -41.07M | -32.97M | -0.66 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-08-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-13 | Eingeleitet | B. Riley FBR | Buy |
| 2017-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-28 | Bestätigt | H.C. Wainwright | Buy |
| 2017-10-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-03-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Herabstufung | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Herabstufung | ROTH Capital | Buy → Sell |
| 2016-03-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2015-09-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-08-01 | Herabstufung | Aegis Capital | Buy → Hold |
| 2014-07-30 | Bestätigt | MLV & Co | Buy |
| 2014-07-29 | Bestätigt | MLV & Co | Buy |
| 2014-04-02 | Bestätigt | MLV & Co | Buy |
| 2014-02-10 | Bestätigt | Aegis Capital | Buy |
| 2014-01-09 | Bestätigt | Aegis Capital | Buy |
| 2013-12-03 | Eingeleitet | MLV & Co | Buy |
| 2013-08-19 | Bestätigt | Aegis Capital | Buy |
Alle ansehen
Galectin Therapeutics Inc Aktie (GALT) Neueste Nachrichten
Non-alcoholic Steatohepatitis (NASH) Treatment Market 2032: Clinical Trials, Medication, EMA, PDMA, FDA Approvals, Epidemiology, Therapies, Companies by DelveInsight - The Globe and Mail
StockNews.com Upgrades Galectin Therapeutics (NASDAQ:GALT) to "Hold" - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by StockNews.com - Defense World
Non-alcoholic Steatohepatitis Treatment Market Projected to Show Strong Growth - openPR
Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times
Galectin Therapeutics Advances NAVIGATE Trial for MASH Cirrhosis Treatment, December Readout on Track | GALT Stock News - StockTitan
HC Wainwright Analysts Decrease Earnings Estimates for GALT - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Earns Buy Rating from HC Wainwright - MarketBeat
Galectin Therapeutics Reports Increased Q3 Losses - TipRanks
Galectin Therapeutics Inc (GALT) Quarterly 10-Q Report - Quartzy
Galectin Therapeutics Advances Galectin-Based Therapeutics Pipeline - TipRanks
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update - The Manila Times
electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21 - The Manila Times
Galectin Q3 Loss Narrows to $11.2M; Key NAVIGATE Trial Results Due December | GALT Stock News - StockTitan
Galectin Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Global Dermatological Drugs Market to Cross USD 31 Billion by 2030 | DelveInsight - The Malaysian Reserve
Galectin Therapeutics (NASDAQ: GALT): Disrupting Merck’s Cancer Dominance - Insider Financial
Individual investors who hold 54% of Galectin Therapeutics Inc. (NASDAQ:GALT) gained 12%, insiders profited as well - Simply Wall St
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking Therapeutics, Madrigal - Barchart
Non-Alcoholic Steatohepatitis Market to Show Remarkable - openPR
Psoriasis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, Therapeutic Innovations, and Recent Developments | Astrazeneca, Bayer, Sanofi, Pfizer, Merck, Novartis - Barchart
Liver Cirrhosis Pipeline Trends 2024: Clinical Trials, - openPR
LIVER CIRRHOSIS MARKET TO GROW AT A SUBSTANTIAL GROWTH RATE - openPR
Galectin therapeutics director Eldred Kary buys $1,300 in stock By Investing.com - Investing.com South Africa
Galectin therapeutics director Eldred Kary buys $1,300 in stock - Investing.com
Galectin therapeutics director Freeman buys $27,000 in stock By Investing.com - Investing.com Canada
Galectin therapeutics director Freeman buys $27,000 in stock - Investing.com
Galectin Therapeutics Inc. (NASDAQ:GALT) Director Purchases $13,500.00 in Stock - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Upgraded to Hold at StockNews.com - Defense World
Application Monitoring Suites Market Size and Industry Overview - News in Assen
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - The Manila Times
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: - openPR
Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Nonalcoholic Steatohepatitis Treatment Market Size, Innovations Driving Market Evolution (2024-2034) - IndiaPolitics.com
Marshall Wace LLP Buys New Shares in Security National Financial Co. (NASDAQ:SNFCA) - Defense World
Marshall Wace LLP Cuts Stock Holdings in ARC Document Solutions, Inc. (NYSE:ARC) - Defense World
AXT, Inc. (NASDAQ:AXTI) Stock Holdings Trimmed by Marshall Wace LLP - Defense World
The Manufacturers Life Insurance Company Has $951,000 Stock Holdings in Huntsman Co. (NYSE:HUN) - Defense World
Marshall Wace LLP Buys New Holdings in Hanesbrands Inc. (NYSE:HBI) - Defense World
Research Analysts’ Updated EPS Estimates for October 6th (APVO, CNP, FDX, FLNT, FRD, GALT, HOPE, KBR, LSXMK, NVGS) - Defense World
Galectin Therapeutics (NASDAQ:GALT) Rating Increased to Hold at StockNews.com - Defense World
Galectin Therapeutics (NASDAQ:GALT) Upgraded at StockNews.com - MarketBeat
Global Non-Alcoholic Steatohepatitis Treatment Market Overview And Statistics For 2024-2033 - EIN News
Ipsen's IQIRVO Approval Has Intensified the Primary Biliary Cholangitis Market Space | DelveInsight - The Malaysian Reserve
Rhumbline Advisers Purchases New Holdings in Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference - The Manila Times
Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - The Manila Times
Galectin Therapeutics (FRA:PHPN) Interest Expense : €-3.71 Mil (TTM As of Jun. 2024) - GuruFocus.com
Galectin Therapeutics (FRA:PHPN) Change In Prepaid Assets : €-0.16 Mil (TTM As of Jun. 2024) - GuruFocus.com
Finanzdaten der Galectin Therapeutics Inc-Aktie (GALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):